LAB Fluidigm: Net earnings per share for the last four quarters
Standard BioTools Inc. is increasing efficiency through oncology alliances and post-merger synergies. The rolling annual change in net income per share visualizes this trend, where the 47.00 metric determines this level. Monopoly influence driven by unique reagents strengthens pricing power, while an aging population guarantees sustainable demand regardless of economic cycles.
LAB (Fluidigm): analytical breakdowns and indicator data
- market price and analyst price targets:
- company stock capitalization data:
- book value of equity indicators:
- debt and liquidity data:
Total Debt to Capital Standard BioTools Inc.|LAB - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Standard BioTools Corp|LAB - Company Aggregate Debts|Debt to Book Value Ratio Standard BioTools Inc|LAB - Company Long-Term Debts|Company Short-Term Debts Standard BioTools|Intermediate Coverage Ratio fluidigm.com
- business earnings and investment ratios data:
LAB - Net Profit|Net Profit Forecast Standard BioTools Inc.|LAB - Price to Earnings Ratio|Future Price to Earnings Multiple Standard BioTools Inc|LAB - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Standard BioTools Inc|LAB - Operating profit EBITDA|Net earnings per share for the last four quarters Standard BioTools|LAB - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months fluidigm.com|LAB - Net earnings per share growth this year|Projected earnings per share increase next year Standard BioTools Inc.
Fundamental company valuation:fluidigm.com, LAB
This indicator determines investment resilience via the rolling annual growth rate of earnings per share, measuring the efficiency of business capitalization amid expensive debt financing. By analyzing the annual dynamics of net income per share TTM, an investor can see the results of cost optimization at Standard BioTools Inc. (LAB) following the merger and the gradual unveiling of operating leverage as equipment sales scale.
Competitor analysis for Standard BioTools Inc.
Net earnings per share for the last four quarters agilent.com A|Quest Diagnostics Incorporated (DGX) - Earnings per share for the last twelve months|ILMN - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Cologuard|Revvity Corp (RVTY) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months BIO (Bio-Rad Laboratories)|Earnings per share for the last four quarters NNNN|Net earnings per share (EPS TTM) SHC (Sotera Health)|Net earnings per share (EPS TTM) Quidel Corporation QDEL|OPK - Earnings per share for the last twelve months|CDNA (CareDx, Inc) - Earnings per share for the last 12 months|MRVI: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months FLGT|CTKB (Cytek Biosciences) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) OraSure Technologies, Inc.|Earnings per share for the last twelve months Exagen Inc. (XGN)|MDXH (MDxHealth, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) LUCD (Lucid Diagnostics Inc.)|PRE: Earnings per share for the last 12 months|IMDX: Net earnings per share for the last 12 months|Earnings per share for the trailing year TRIB (Trinity Biotech plc)|PRPH: Net earnings per share (EPS TTM)|AIMD (Ainos Corporation) - Earnings per share for the last twelve months|CODX (Co-Diagnostics, Inc.) - Net earnings per share (EPS TTM)|heartsciences.com (HSCS) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Biomerica (BMRA)|CDIO - Net earnings per one share for the last twelve months|Onconetix Corp - Net earnings per share for the last 12 months|Earnings per share for the last four quarters VRAX (Virax Biolabs Corp)|BJDX - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months aspirawh.com|Accelerate Diagnostics, Inc. (AXDX) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months centogene.com (CNTG)|Earnings per share for the last twelve months Enzo Biochem Inc.|Earnings per share for the last twelve months FRES|Earnings per share for the last twelve months Genetic Technologies (GENE)|Net earnings per share for the last four quarters 23andme.com|Psychemedics Corporation - Net earnings per share for the last 12 months
